AnaBios
David is a General Partner with Ampersand Capital. Prior to joining Ampersand in 2010, David spent six years with Covington Associates, a specialty investment bank focused on middle-market M&A in the healthcare sector. Prior to Covington, he spent five years as a consultant for Boston Healthcare Associates. David’s current and past board seats include Genezen, ArrantaBio, StageBio, Protogene, BioClinica, BrammerBio, Vernal Biosciences and Vibalogics.
David holds a B.Sc. from the University of Aberdeen, Scotland, a Ph.D. in Immunology from the University of Sheffield, England, and a M.B.A. from Babson College, Wellesley, MA.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
AnaBios
AnaBios generates highly valuable, predictive human data in advance of clinical trials, ensuring the selection of the most effective and safest drugs, thereby reducing the time and expense related to clinical trial failures.